Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study
Abstract Background A paradigm shift has occurred in cancer chemotherapy from tumor‐specific treatment with cytotoxic agents to personalized medicine with molecular‐targeted drugs. Thus, it is essential to identify genomic alterations and molecular features to recommend effective targeted molecular...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5349 |
| _version_ | 1827986475296227328 |
|---|---|
| author | Hidekazu Shirota Keigo Komine Masanobu Takahashi Shin Takahashi Eisaku Miyauchi Hidetaka Niizuma Hiroshi Tada Muneaki Shimada Tetsuya Niihori Yoko Aoki Ikuko Sugiyama Maako Kawamura Jun Yasuda Shuhei Suzuki Takeshi Iwaya Motonobu Saito Tsuyoshi Saito Hiroyuki Shibata Toru Furukawa Chikashi Ishioka |
| author_facet | Hidekazu Shirota Keigo Komine Masanobu Takahashi Shin Takahashi Eisaku Miyauchi Hidetaka Niizuma Hiroshi Tada Muneaki Shimada Tetsuya Niihori Yoko Aoki Ikuko Sugiyama Maako Kawamura Jun Yasuda Shuhei Suzuki Takeshi Iwaya Motonobu Saito Tsuyoshi Saito Hiroyuki Shibata Toru Furukawa Chikashi Ishioka |
| author_sort | Hidekazu Shirota |
| collection | DOAJ |
| description | Abstract Background A paradigm shift has occurred in cancer chemotherapy from tumor‐specific treatment with cytotoxic agents to personalized medicine with molecular‐targeted drugs. Thus, it is essential to identify genomic alterations and molecular features to recommend effective targeted molecular medicines regardless of the tumor site. Nevertheless, it takes considerable expertise to identify treatment targets from primary‐sequencing data in order to provide drug recommendations. The Molecular Tumor Board (MTB) denotes a platform that integrates clinical and molecular features for clinical decisions. Methods This study retrospectively analyses all the cases of discussion and decision at the MTB in Tohoku University Hospital and summarizes genetic alterations and treatment recommendations. Results The MTB discussed 1003 comprehensive genomic profiling (CGP) tests conducted in patients with solid cancer, and the resulting rate of assessing treatment recommendations was approximately 19%. Among hundreds of genes in the CGP test, only 30 genetic alterations or biomarkers were used to make treatment recommendations. The leading biomarkers that led to treatment recommendations were tumor mutational burden‐high (TMB‐H) (n = 32), ERBB2 amplification (n = 24), BRAF V600E (n = 16), and BRCA1/2 alterations (n = 32). Thyroid cancer accounted for most cancer cases for which treatment recommendation was provided (81.3%), followed by non‐small cell lung cancer (42.4%) and urologic cancer (31.3%). The number of tests performed for gastrointestinal cancers was high (n = 359); however, the treatment recommendations for the same were below average (13%). Conclusion The results of this study may be used to simplify treatment recommendations from the CGP reports and help select patients for testing, thereby increasing the accuracy of personalized medicine. |
| first_indexed | 2024-04-09T23:30:52Z |
| format | Article |
| id | doaj.art-8a80aeda87b14dc480de839989bfda14 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T23:30:52Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-8a80aeda87b14dc480de839989bfda142023-03-21T05:20:41ZengWileyCancer Medicine2045-76342023-03-011256170618110.1002/cam4.5349Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational studyHidekazu Shirota0Keigo Komine1Masanobu Takahashi2Shin Takahashi3Eisaku Miyauchi4Hidetaka Niizuma5Hiroshi Tada6Muneaki Shimada7Tetsuya Niihori8Yoko Aoki9Ikuko Sugiyama10Maako Kawamura11Jun Yasuda12Shuhei Suzuki13Takeshi Iwaya14Motonobu Saito15Tsuyoshi Saito16Hiroyuki Shibata17Toru Furukawa18Chikashi Ishioka19Department of Clinical Oncology Tohoku University Hospital Sendai JapanDepartment of Clinical Oncology Tohoku University Hospital Sendai JapanDepartment of Clinical Oncology Tohoku University Hospital Sendai JapanDepartment of Clinical Oncology Tohoku University Hospital Sendai JapanDepartment of Respiratory Medicine Tohoku University Graduate School of Medicine Sendai JapanDepartment of Pediatrics Tohoku University School of Medicine Sendai JapanDepartment of Breast and Endocrine Surgical Oncology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Obstetrics and Gynecology Tohoku University School of Medicine Sendai JapanDepartment of Medical Genetics Tohoku University Graduate School of Medicine Sendai JapanDepartment of Medical Genetics Tohoku University Graduate School of Medicine Sendai JapanPersonalized Medicine Center Tohoku University Hospital Sendai JapanPersonalized Medicine Center Tohoku University Hospital Sendai JapanDivision of Molecular Cellular Oncology Miyagi Cancer Center Research Institute Natori JapanDepartment of Clinical Oncology Yamagata University Faculty of Medicine Yamagata JapanMolecular Therapeutics Laboratory, Department of Surgery Iwate Medical University School of Medicine Morioka JapanDepartment of Gastrointestinal Tract Surgery Fukushima Medical University School of Medicine Fukushima JapanDepartment of Breast Surgery Japanese Red Cross Saitama Hospital Saitama JapanDepartment of Clinical Oncology, Graduate School of Medicine Akita University Akita JapanDepartment of Investigative Pathology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Clinical Oncology Tohoku University Hospital Sendai JapanAbstract Background A paradigm shift has occurred in cancer chemotherapy from tumor‐specific treatment with cytotoxic agents to personalized medicine with molecular‐targeted drugs. Thus, it is essential to identify genomic alterations and molecular features to recommend effective targeted molecular medicines regardless of the tumor site. Nevertheless, it takes considerable expertise to identify treatment targets from primary‐sequencing data in order to provide drug recommendations. The Molecular Tumor Board (MTB) denotes a platform that integrates clinical and molecular features for clinical decisions. Methods This study retrospectively analyses all the cases of discussion and decision at the MTB in Tohoku University Hospital and summarizes genetic alterations and treatment recommendations. Results The MTB discussed 1003 comprehensive genomic profiling (CGP) tests conducted in patients with solid cancer, and the resulting rate of assessing treatment recommendations was approximately 19%. Among hundreds of genes in the CGP test, only 30 genetic alterations or biomarkers were used to make treatment recommendations. The leading biomarkers that led to treatment recommendations were tumor mutational burden‐high (TMB‐H) (n = 32), ERBB2 amplification (n = 24), BRAF V600E (n = 16), and BRCA1/2 alterations (n = 32). Thyroid cancer accounted for most cancer cases for which treatment recommendation was provided (81.3%), followed by non‐small cell lung cancer (42.4%) and urologic cancer (31.3%). The number of tests performed for gastrointestinal cancers was high (n = 359); however, the treatment recommendations for the same were below average (13%). Conclusion The results of this study may be used to simplify treatment recommendations from the CGP reports and help select patients for testing, thereby increasing the accuracy of personalized medicine.https://doi.org/10.1002/cam4.5349C‐CATcomprehensive genomic profilingmolecular tumor Boardpersonalized medicinesolid cancer |
| spellingShingle | Hidekazu Shirota Keigo Komine Masanobu Takahashi Shin Takahashi Eisaku Miyauchi Hidetaka Niizuma Hiroshi Tada Muneaki Shimada Tetsuya Niihori Yoko Aoki Ikuko Sugiyama Maako Kawamura Jun Yasuda Shuhei Suzuki Takeshi Iwaya Motonobu Saito Tsuyoshi Saito Hiroyuki Shibata Toru Furukawa Chikashi Ishioka Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study Cancer Medicine C‐CAT comprehensive genomic profiling molecular tumor Board personalized medicine solid cancer |
| title | Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study |
| title_full | Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study |
| title_fullStr | Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study |
| title_full_unstemmed | Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study |
| title_short | Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study |
| title_sort | clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in japan a retrospective observational study |
| topic | C‐CAT comprehensive genomic profiling molecular tumor Board personalized medicine solid cancer |
| url | https://doi.org/10.1002/cam4.5349 |
| work_keys_str_mv | AT hidekazushirota clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT keigokomine clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT masanobutakahashi clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT shintakahashi clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT eisakumiyauchi clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT hidetakaniizuma clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT hiroshitada clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT muneakishimada clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT tetsuyaniihori clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT yokoaoki clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT ikukosugiyama clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT maakokawamura clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT junyasuda clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT shuheisuzuki clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT takeshiiwaya clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT motonobusaito clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT tsuyoshisaito clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT hiroyukishibata clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT torufurukawa clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy AT chikashiishioka clinicaldecisionsbythemoleculartumorboardoncomprehensivegenomicprofilingtestsinjapanaretrospectiveobservationalstudy |